Home Alzheimer’s Disease Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC

Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC

The phase III KEYNOTE-177 study demonstrated that front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival (PFS) versus standard of care chemotherapy in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).1

The randomized, open-label, phase III trial, presented during a 2020 ASCO Virtual Scientific Program press briefing, is the first in which pembrolizumab has been shown to benefit these patients when used as a front-line therapy. 

“These long-awaited trial results will change clinical practice,” lead author Thierry André, MD, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.2 “Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments